

Table 1 List of primers used for RT-PCR.

Gene name	Species	(5') Sense primers (3')	(5')Antisense primers (3')
GAPDH	Ms	ACCACAGTCCATGCCATCAC	TCCACCACCCTGTTGCTGTA
HoxB4	Hs	AGAGGCGAGAGAGCAGCTT	TTCCTTCTCCAGCTCCAAGA
Oct-3/4	Ms	GTTTGCCAAGCTGCTGAAGC	TCTAGCCCAAGCTGATTGGC
GFP	—	CACATGAAGCAGCACGACTT	TGCTCAGGTAGTGGTTGTCTG
Flk-1	Ms	TCTGTGGTTCTGCGTGGAGA	GTATCATTTCCAACCACCC
Gata1	Ms	TTGTGAGGCCAGAGAGTGTG	TTCCTCGTCTGGATTCCATC
Gata1 (real-time PCR)	Ms	GTCAGAACC GGCTCTCATC	GTGGTCGTTTGACAGTTAGTGCAT
Tel	Ms	CTGAAGCAGAGGAAATCTCGAATG	GGCAGGCAGTGATTATTCTCGA
c-myb	Ms	CCTCACCTCCATCTCAGCTC	GCTGGTGAGGCACTTTCTTC
β-H1	Ms	AGTCCCCATGGAGTCAAAGA	CTCAAGGAGACCTTTGCTCA
β-Major	Ms	CTGACAGATGCTCTCTTGGG	CACAACCCAGAAACAGACA
CXCR4	Ms	GTCTATGTGGGCGTCTGGAT	GGCAGAGCTTTTGAAC TTGG

(PBS/2%FBS). Dead cells were excluded from the analysis by 7-amino actinomycin D (7-AAD, eBioscience). Analysis was performed on an LSRFortessa flow cytometer by using FACS-Diva software (BD Bioscience). For detection of transgene expression by Ad vectors, EB-derived total cells or CD41⁺c-kit⁺ cells were transduced with Ad-DsRed or Ad-CA-GFP, respectively, for 1.5 h. At 48 h of incubation with the hematopoietic cytokines as described above, transgene expression in the cells was analyzed by flow cytometry.

Colony assay

A colony-forming assay was performed by plating ES cell-derived hematopoietic cells or iPS cell-derived hematopoietic cells into methylcellulose medium M3434 (Stem Cell Technologies, Vancouver, BC, Canada). After incubation at 37 °C and 5% CO₂ for 10 to 14 days in a humidified atmosphere, colony numbers were counted. The morphology of colonies was observed using an inverted light microscope.

RT-PCR

Total RNA was isolated with the use of ISOGENE (Nippon Gene, Tokyo, Japan). cDNA was synthesized by using SuperScript II reverse transcriptase (Invitrogen) and the oligo(dT) primer. Semi-quantitative PCR was performed with the use of TaKaRa ExTaq HS DNA polymerase (Takara, Shiga, Japan). The PCR conditions were 94 °C for 2 min, followed by the appropriate number of cycles of 94 °C for 15 s, 55 °C for 30 s with 72 °C for 30 s and a final extension of 72 °C for 1 min, except for the addition of 5% dimethyl sulfoxide in the case of hHoxB4 cDNA amplification. The product was assessed by 2% agarose gel electrophoresis followed by ethidium bromide staining. Quantitative real-time PCR was performed using StepOnePlus real-time PCR system with FAST SYBR Green Master Mix (Applied Biosystems, Foster-City, CA). The sequences of the primers used for in this study are listed in Table 1.

Supplementary materials related to this article can be found online at doi:10.1016/j.scr.2011.09.001.

Conflict of interest

The authors have no financial conflict of interest.

Acknowledgments

We thank Dr. S. Yamanaka for kindly providing the mouse iPS cell line 38C2 and 20D17. We would also like to thank Dr. J. Miyazaki and Dr. T. Imai for providing the CA promoter and anti-mouse CAR monoclonal antibody, respectively. We also thank Dr. K. Nishikawa (National Institute of Biomedical Innovation) for helpful comments. This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan and the Ministry of Health, Labour, and Welfare of Japan.

References

Arai, F., Hirao, A., Ohmura, M., Sato, H., Matsuoka, S., Takubo, K., Ito, K., Koh, G.Y., Suda, T., 2004. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell* 118, 149–161.

Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., Finberg, R.W., 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* 275, 1320–1323.

Bowles, K.M., Vallier, L., Smith, J.R., Alexander, M.R., Pedersen, R.A., 2006. HOXB4 overexpression promotes hematopoietic development by human embryonic stem cells. *Stem Cells* 24, 1359–1369.

Carson, S.D., 2000. Limited proteolysis of the coxsackievirus and adenovirus receptor (CAR) on HeLa cells exposed to trypsin. *FEBS Lett.* 484, 149–152.

Chadwick, K., Wang, L., Li, L., Menendez, P., Murdoch, B., Rouleau, A., Bhatia, M., 2003. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. *Blood* 102, 906–915.

Evans, M.J., Kaufman, M.H., 1981. Establishment in culture of pluripotent cells from mouse embryos. *Nature* 292, 154–156.

Godin, I., Cumano, A., 2002. The hare and the tortoise: an embryonic haematopoietic race. *Nat. Rev. Immunol.* 2, 593–604.

- Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A., Cavazzana-Calvo, M., 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 302, 415–419.
- Inamura, M., Kawabata, K., Takayama, K., Tashiro, K., Sakurai, F., Katayama, K., Toyoda, M., Akutsu, H., Miyagawa, Y., Okita, H., Kiyokawa, N., Umezawa, A., Hayakawa, T., Furue, M.K., Mizuguchi, H., 2011. Efficient generation of hepatoblasts from human ES cells and iPS cells by transient overexpression of homeobox gene HEX. *Mol. Ther.* 19, 400–407.
- Kawabata, K., Sakurai, F., Yamaguchi, T., Hayakawa, T., Mizuguchi, H., 2005. Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. *Mol. Ther.* 12, 547–554.
- Keller, G., 2005. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. *Genes Dev.* 19, 1129–1155.
- Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji, H., Ehrlich, L.I., Yabuuchi, A., Takeuchi, A., Cuniff, K.C., Hongguang, H., McKinney-Freeman, S., Naveiras, O., Yoon, T.J., Irizarry, R.A., Jung, N., Seita, J., Hanna, J., Murakami, P., Jaenisch, R., Weissleder, R., Orkin, S.H., Weissman, I.L., Feinberg, A.P., Daley, G.Q., 2010. Epigenetic memory in induced pluripotent stem cells. *Nature* 467, 285–290.
- Kulkeaw, K., Horio, Y., Mizuochi, C., Ogawa, M., Sugiyama, D., 2010. Variation in hematopoietic potential of induced pluripotent stem cell lines. *Stem Cell Rev.* 6, 381–389.
- Kurita, R., Sasaki, E., Yokoo, T., Hiroyama, T., Takasugi, K., Imoto, H., Izawa, K., Dong, Y., Hashiguchi, T., Soda, Y., Maeda, T., Suehiro, Y., Tanioka, Y., Nakazaki, Y., Tani, K., 2006. Tal1/Scl gene transduction using a lentiviral vector stimulates highly efficient hematopoietic cell differentiation from common marmoset (*Callithrix jacchus*) embryonic stem cells. *Stem Cells* 24, 2014–2022.
- Kyba, M., Perlangeiro, R.C., Daley, G.Q., 2002. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. *Cell* 109, 29–37.
- Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H.G., Fehse, B., Baum, C., 2002. Murine leukemia induced by retroviral gene marking. *Science* 296, 497.
- Maizel Jr., J.V., White, D.O., Scharff, M.D., 1968. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* 36, 115–125.
- Matsumoto, K., Isagawa, T., Nishimura, T., Ogaeri, T., Eto, K., Miyazaki, S., Miyazaki, J., Aburatani, H., Nakauchi, H., Ema, H., 2009. Stepwise development of hematopoietic stem cells from embryonic stem cells. *PLoS One* 4, e4820.
- McKinney-Freeman, S.L., Naveiras, O., Yates, F., Loewer, S., Philitas, M., Curran, M., Park, P.J., Daley, G.Q., 2009. Surface antigen phenotypes of hematopoietic stem cells from embryos and murine embryonic stem cells. *Blood* 114, 268–278.
- Mikkola, H.K., Fujiwara, Y., Schlaeger, T.M., Traver, D., Orkin, S.H., 2003. Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse embryo. *Blood* 101, 508–516.
- Mitjavila-Garcia, M.T., Cailleret, M., Godin, I., Nogueira, M.M., Cohen-Solal, K., Schiavon, V., Lecluse, Y., Le Pesteur, F., Lagrue, A.H., Vainchenker, W., 2002. Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. *Development* 129, 2003–2013.
- Mizuguchi, H., Kay, M.A., 1998. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. *Hum. Gene Ther.* 9, 2577–2583.
- Mizuguchi, H., Kay, M.A., 1999. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. *Hum. Gene Ther.* 10, 2013–2017.
- Nakano, T., Kodama, H., Honjo, T., 1994. Generation of lymphohematopoietic cells from embryonic stem cells in culture. *Science* 265, 1098–1101.
- Niwa, H., Yamamura, K., Miyazaki, J., 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108, 193–199.
- Okabe, M., Otsu, M., Ahn, D.H., Kobayashi, T., Morita, Y., Wakiyama, Y., Onodera, M., Eto, K., Ema, H., Nakauchi, H., 2009. Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. *Blood* 114, 1764–1767.
- Okita, K., Ichisaka, T., Yamanaka, S., 2007. Generation of germline-competent induced pluripotent stem cells. *Nature* 448, 313–317.
- Pilat, S., Carotta, S., Schiedlmeier, B., Kamino, K., Mairhofer, A., Will, E., Modlich, U., Steinlein, P., Ostertag, W., Baum, C., Beug, H., Klump, H., 2005. HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. *Proc. Natl. Acad. Sci. U. S. A.* 102, 12101–12106.
- Polo, J.M., Liu, S., Figueroa, M.E., Kulalert, W., Eminli, S., Tan, K.Y., Apostolou, E., Stadtfeld, M., Li, Y., Shioda, T., Natesan, S., Wagers, A.J., Melnick, A., Evans, T., Hochedlinger, K., 2010. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat. Biotechnol.* 28, 848–855.
- Schiedlmeier, B., Santos, A.C., Ribeiro, A., Moncaut, N., Lesinski, D., Auer, H., Kornacker, K., Ostertag, W., Baum, C., Mallo, M., Klump, H., 2007. HOXB4's road map to stem cell expansion. *Proc. Natl. Acad. Sci. U. S. A.* 104, 16952–16957.
- Schmitt, T.M., de Pooter, R.F., Gronski, M.A., Cho, S.K., Ohashi, P.S., Zuniga-Pflucker, J.C., 2004. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. *Nat. Immunol.* 5, 410–417.
- Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663–676.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
- Tashiro, K., Kawabata, K., Sakurai, H., Kurachi, S., Sakurai, F., Yamanishi, K., Mizuguchi, H., 2008. Efficient adenovirus vector-mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation. *J. Gene Med.* 10, 498–507.
- Tashiro, K., Inamura, M., Kawabata, K., Sakurai, F., Yamanishi, K., Hayakawa, T., Mizuguchi, H., 2009. Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. *Stem Cells* 27, 1802–1811.
- Tashiro, K., Kawabata, K., Inamura, M., Takayama, K., Furukawa, N., Sakurai, F., Katayama, K., Hayakawa, T., Furue, M.K., Mizuguchi, H., 2010. Adenovirus vector-mediated efficient transduction into human embryonic and induced pluripotent stem cells. *Cell. Reprogram.* 12, 501–507.
- Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., Jones, J.M., 1998. Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145–1147.
- Tomko, R.P., Xu, R., Philipson, L., 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc. Natl. Acad. Sci. U. S. A.* 94, 3352–3356.

- Vodyanik, M.A., Bork, J.A., Thomson, J.A., Slukvin, I.I., 2005. Human embryonic stem cell-derived CD34⁺ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. *Blood* 105, 617–626.
- Wang, Y., Yates, F., Naveiras, O., Ernst, P., Daley, G.Q., 2005. Embryonic stem cell-derived hematopoietic stem cells. *Proc. Natl. Acad. Sci. U. S. A.* 102, 19081–19086.
- Williams, D., Baum, C., 2004. Gene therapy needs both trials and new strategies. *Nature* 429, 129.
- Zhang, X.B., Beard, B.C., Trobridge, G.D., Wood, B.L., Sale, G.E., Sud, R., Humphries, R.K., Kiem, H.P., 2008. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. *J. Clin. Invest.* 118, 1502–1510.

Efficient and Directive Generation of Two Distinct Endoderm Lineages from Human ESCs and iPSCs by Differentiation Stage-Specific SOX17 Transduction

Kazuo Takayama^{1,2}, Mitsuru Inamura^{1,2}, Kenji Kawabata^{2,3}, Katsuhisa Tashiro², Kazufumi Katayama¹, Fuminori Sakurai¹, Takao Hayakawa^{4,5}, Miho Kusuda Furue^{6,7}, Hiroyuki Mizuguchi^{1,2,8*}

1 Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan, **2** Laboratory of Stem Cell Regulation, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan, **3** Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan, **4** Pharmaceuticals and Medical Devices Agency, Chiyoda-ku, Tokyo, Japan, **5** Pharmaceutical Research and Technology Institute, Kinki University, Higashiosaka, Osaka, Japan, **6** JCRB Cell Bank, Division of Bioresources, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan, **7** Laboratory of Cell Processing, Institute for Frontier Medical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan, **8** The Center for Advanced Medical Engineering and Informatics, Osaka University, Suita, Osaka, Japan

Abstract

The establishment of methods for directive differentiation from human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) is important for regenerative medicine. Although Sry-related HMG box 17 (SOX17) overexpression in ESCs leads to differentiation of either extraembryonic or definitive endoderm cells, respectively, the mechanism of these distinct results remains unknown. Therefore, we utilized a transient adenovirus vector-mediated overexpression system to mimic the SOX17 expression pattern of embryogenesis. The number of alpha-fetoprotein-positive extraembryonic endoderm (ExEn) cells was increased by transient SOX17 transduction in human ESC- and iPSC-derived primitive endoderm cells. In contrast, the number of hematopoietically expressed homeobox (HEX)-positive definitive endoderm (DE) cells, which correspond to the anterior DE *in vivo*, was increased by transient adenovirus vector-mediated SOX17 expression in human ESC- and iPSC-derived mesendoderm cells. Moreover, hepatocyte-like cells were efficiently generated by sequential transduction of SOX17 and HEX. Our findings show that a stage-specific transduction of SOX17 in the primitive endoderm or mesendoderm promotes directive ExEn or DE differentiation by SOX17 transduction, respectively.

Citation: Takayama K, Inamura M, Kawabata K, Tashiro K, Katayama K, et al. (2011) Efficient and Directive Generation of Two Distinct Endoderm Lineages from Human ESCs and iPSCs by Differentiation Stage-Specific SOX17 Transduction. PLoS ONE 6(7): e21780. doi:10.1371/journal.pone.0021780

Editor: Patrick Callaerts, VIB & Katholieke Universiteit Leuven, Belgium

Received: February 3, 2011; **Accepted:** June 8, 2011; **Published:** July 7, 2011

Copyright: © 2011 Takayama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: HM, MKF, and TH were supported by grants from the Ministry of Health, Labor, and Welfare of Japan. K. Kawabata was supported by grants from the Ministry of Education, Sports, Science and Technology of Japan (20200076) and the Ministry of Health, Labor, and Welfare of Japan. K. Katayama was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: mizuguch@phs.osaka-u.ac.jp

Introduction

There are two distinct endoderm lineages in early embryogenesis, the extraembryonic endoderm (ExEn) and the definitive endoderm (DE). The first of these lineages, the ExEn plays crucial roles in mammalian development, although it does not contribute to the formation of body cells. In early embryogenesis, a part of the inner cell mass of the blastocyst differentiates into the primitive endoderm (PrE). The PrE differentiates into the ExEn that composes the parietal endoderm, which contributes to the primary yolk sac, and the visceral endoderm, which overlies the epiblast [1,2]. In contrast, the second of the endoderm lineages, the DE arises from the primitive streak (PS), which is called the mesendoderm [3]. The DE has the ability to differentiate into the hepatic and pancreatic tissue [4].

The establishment of human embryonic stem cells (ESCs) [5] and human induced pluripotent stem cells (iPSCs) [6,7] has opened up new opportunities for basic research and regenerative medicine. To exploit the potential of human ESCs and iPSCs, it is

necessary to understand the mechanisms of their differentiation. Although growth factor-mediated ExEn or DE differentiation is widely performed, it leads to a heterogeneous population [8,9,10,11]. Several studies have utilized not only growth factors but also modulation of transcription factors to control downstream signaling cascades [10,12,13]. Sox17, an Sry-related HMG box transcription factor, is required for development of both the ExEn and DE. In mice, during ExEn and DE development, Sox17 expression is first observed in the PrE and in the anterior PS, respectively [14]. Previous study showed that stable Sox17 overexpression promotes ExEn differentiation from mouse ESCs [12]. On the other hand, another previous study has demonstrated that DE progenitors can be established from human ESCs by stable expression of SOX17 [10]. The mechanism of these discrepancies which occurs in SOX17 transduction still remains unknown. Also, the role of SOX17 in human ExEn differentiation still remains unknown. Therefore, it is quite difficult to promote directive differentiation into either ExEn or DE cells by SOX17 transduction.




Figure 1. Efficient ExEn differentiation from human ESC- and iPSC-derived PrE cells by SOX17 transduction. (A–D) Undifferentiated human ESCs (H9) and BMP4-induced human ESC-derived cells, which were cultured with the medium containing BMP4 (20 ng/ml) for 0, 1, 2, 3, and 4 days, were transduced with 3,000 VP/cell of Ad-SOX17 for 1.5 h. Ad-SOX17-transduced cells were cultured with 20 ng/ml of BMP4, and then the gene expression levels of (A) the ExEn markers (AFP, GATA4, LAMB1, and SOX7), (B) the trophectoderm markers (CDX2, GATA2, hCGα, and hCGβ), (C) the pluripotent marker (NANOG), and (D) the DE marker (GSC) were examined by real-time RT-PCR on day 5 of differentiation. The horizontal axis represents the day on which the cells were transduced with Ad-SOX17. The expression levels of undifferentiated human ESCs on day 0 were defined 1.0. (E) On day 1, human ESC-derived PrE cells, which were cultured with the medium containing BMP4 for 1 day, were transduced with Ad-LacZ or Ad-SOX17 and cultured until day 5. The ExEn cells were subjected to immunostaining with anti-AFP or anti-SOX7 antibodies, and then analyzed by flow cytometry. (F) After Ad-LacZ or Ad-SOX17 transduction, the efficacies of ExEn differentiation from the human ES cell line (H9) and the three human iPSC cell lines (201B7, Dotcom, and Tic) were compared on day 5 of differentiation. All data are represented as the means ± SD ($n = 3$). doi:10.1371/journal.pone.0021780.g001

In this study, we utilized SOX17 as a stage-specific regulator of ExEn and DE differentiation from human ESCs and iPSCs. The human ESC- and iPSC-derived cells were transduced with SOX17-expressing adenovirus vector (Ad-SOX17), and the resulting phenotypes were assessed for their ability to differentiate into ExEn and DE cells *in vitro*. In addition, we examined whether SOX17-transduced cells have the ability to differentiate into the hepatic lineage. The results showed that stage-specific overexpression of the SOX17 transcription factor promotes directive differentiation into either ExEn or DE cells.

Results

The induction of human ESC-derived PrE cells and human ESC-derived mesendoderm cells

To determine the appropriate stage for SOX17 transduction, ExEn or DE cells were differentiated from human ESCs by a conventional method using BMP4 (20 ng/ml) or Activin A (100 ng/ml), respectively (Figures S1 and S2). Experiments for bidirectional differentiation using BMP4 and Activin A indicated that PrE cells were obtained on day 1 (Figure S1) and mesendoderm

cells were obtained on day 3 (Figure S2). We expected that stage-specific SOX17 transduction into PrE cells or mesendoderm cells could promote ExEn or DE differentiation, because the time period of initiation of SOX17 expression was correlated with the time period of formation of PrE cells (day 1) (Figure S1C) and mesendoderm cells (day 3) (Figure S2C), respectively.

PrE stage-specific SOX17 overexpression promotes directive ExEn differentiation from human ESCs

To examine the effect of forced and transient expression of SOX17 on the differentiation of human ESC- and iPSC-derived cells, we used a fiber-modified adenovirus (Ad) vector containing the EF-1α promoter and a stretch of lysine residues (KKKKKKK, K7) peptides in the C-terminal region of the fiber knob. The K7 peptide targets heparan sulfates on the cellular surface, and the fiber-modified Ad vector containing the K7 peptides has been shown to be efficient for transduction into many kinds of cells [15,16].

Because the time period of initiation of SOX17 expression was correlated with the time period of formation of PrE cells (day 1) (Figure S1), we expected that stage-specific SOX17 transduction

into PrE cells would promote ExEn differentiation. Therefore, we examined the stage-specific role of SOX17 in ExEn differentiation. Ad-SOX17 transduction was performed in human ESCs treated with BMP4 for 0, 1, 2, 3, or 4 days, and the Ad-SOX17-transduced cells were cultured with medium containing BMP4 until day 5 (Figures 1A–1D). We confirmed the expression of exogenous SOX17 in the human ESC-derived mesendoderm cells transduced with Ad-SOX17 (Figure S3). Since BMP4 is known for its capability to induce both ExEn and trophoctoderm [8,9], we analyzed not only the expression levels of ExEn markers but also those of trophoctoderm markers by real-time RT-PCR after 5 days of differentiation (Figures 1A and 1B). The transduction of Ad-SOX17 on day 1 led to the highest expression levels of ExEn markers, alpha-fetoprotein (AFP), GATA4, laminin B1 (LAMB1), and SOX7 [17,18,19]. In contrast, the expression levels of the trophoctoderm markers CDX2, GATA2, hCG α (human chorionic gonadotropin), and hCG β [20] were down-regulated in Ad-SOX17-transduced cells as compared with non-transduced cells (Figure 1B). The expression levels of the pluripotent marker NANOG and DE marker GSC were not increased by SOX17 transduction (Figures 1C and 1D). We confirmed that there were no differences between non-transduced cells and Ad-LacZ-transduced cells in gene expression levels of all the markers investigated in Figures 1A–1D (data not shown). Therefore, we concluded that ExEn cells were efficiently induced from Ad-SOX17-transduced PrE cells.

The effects of SOX17 transduction on the ExEn differentiation from human ESC-derived PrE cells were also assessed by quantifying AFP- or SOX7-positive ExEn cells. The percentage of AFP- or SOX7-positive cells was significantly increased in Ad-SOX17-transduced cells (69.7% and 63.3%, respectively) (Figure 1E). Similar results were observed in the human iPS cell lines (201B7, Dotcom, and Tic) (Figure 1F). These findings indicated that stage-specific SOX17 overexpression in human ESC-derived PrE cells enhances ExEn differentiation.

Mesendoderm stage-specific SOX17 overexpression promotes directive DE differentiation from human ESCs

To examine the effects of transient SOX17 overexpression on DE differentiation from human ESCs, we optimized the timing of the Ad-SOX17 transduction. Ad-SOX17 transduction was performed in human ESCs treated with Activin A (100 ng/ml) for 0, 1, 2, 3, or 4 days, and the Ad-SOX17-transduced cells were cultured with medium containing Activin A (100 ng/ml) until day 5 (Figures 2A–2C). Using a fiber-modified Ad vector, both undifferentiated human ESCs and Activin A-induced human ESC-derived cells were efficiently transduced (Figure S4). The transduction of SOX17 on day 3 led to the highest expression levels of the DE markers FOXA2 [21], GSC [22], GATA4 [17], and HEX [23] (Figure 2A). In contrast to the DE markers, the expression levels of the pluripotent marker NANOG [24] were down-regulated in Ad-SOX17-transduced cells as compared with non-transduced cells (Figure 2B). The expression levels of the ExEn marker SOX7 [14] were up-regulated, when Ad-SOX17 transduction was performed into human ESCs treated with Activin A (100 ng/ml) for 0, 1, or 2 days (Figure 2C). On the other hand, the expression levels of the ExEn marker SOX7 were significantly down-regulated, when Ad-SOX17 transduction was performed into human ESCs treated with Activin A (100 ng/ml) for 3 or 4 days, indicating that SOX17 overexpression prior to mesendoderm formation (day 0, 1, and 2) promoted not only DE differentiation but also ExEn differentiation. Similar results were obtained with the human iPS cell line (Tic) (Figure S5). Although the expression

levels of the mesoderm marker FLK1 [25] did not exhibit any change when Ad-SOX17 transduction was performed into human ESCs treated with Activin A (100 ng/ml) for 0, 1, or 2 days (Figure 2D), their expression levels were significantly down-regulated when Ad-SOX17 transduction was performed into human ESCs treated with Activin A (100 ng/ml) for 3 or 4 days. These results suggest that SOX17 overexpression promotes directive differentiation from mesendoderm cells into the DE cells, but not into mesoderm cells. We also confirmed that Ad-vector mediated gene expression in the human ESC-derived mesendoderm cells (day 3) continued until day 6 and disappeared on day 10 (Figure S6). SOX17 transduction in the human ESC-derived cells on day 3 and 4 had no effect on cell viability, while that in the cells on day 0, 1, and 2 resulted in severely impaired cell viability (Figure S7), probably because SOX17 transduction directed the cells on day 0, 1, and 2 to differentiate into ExEn cells but the medium containing Activin A (100 ng/ml) was inappropriate for ExEn cells. We confirmed that there were no differences between non-transduced cells and Ad-LacZ-transduced cells in gene expression levels of all the markers investigated in Figures 2A–2D (data not shown). These results indicated that stage-specific SOX17 overexpression in human ESC-derived mesendoderm cells is essential for promoting efficient DE differentiation.

It has been previously reported that human ESC-derived mesendoderm cells and DE cells became CXCR4-positive (>80%) by culturing human ESCs with Activin A (100 ng/ml) [26]. However, Activin A is not sufficient for homogenous differentiation of c-Kit/CXCR4-double-positive DE cells [10,11] or HEX-positive anterior DE cells [23]. Seguin et al. and Morrison et al. reported that the differentiation efficiency of c-Kit/CXCR4-double-positive DE cells was approximately 30% in the absence of stable Sox17 expression and that of HEX-positive anterior DE cells was only about 10% [10,23]. Therefore, we next examined whether Ad-SOX17 transduction improves the differentiation efficiency of c-Kit/CXCR4-double-positive DE cells and HEX-positive anterior DE cells. Human ESC-derived mesendoderm cells were transduced with Ad-SOX17, and the number of CXCR4/c-Kit-double-positive cells was analyzed by using a flow cytometer. The percentage of CXCR4/c-Kit-double-positive cells was significantly increased in Ad-SOX17-transduced cells (67.7%), while that in Ad-LacZ-transduced cells was only 22% (Figure 2E). The percentage of HEX-positive cells was also significantly increased in Ad-SOX17-transduced cells (53.7%), while that in Ad-LacZ-transduced cells was approximately 11% (Figure 2F). Similar results were also observed in the three human iPS cell lines (201B7, Dotcom, and Tic) (Figure 2G). These findings indicated that stage-specific SOX17 overexpression in human ESC-derived mesendoderm cells promotes efficient differentiation of DE cells.

Ad-SOX17-transduced cells tend to differentiate into the hepatic lineage

To investigate whether Ad-SOX17-transduced cells have the ability to differentiate into hepatoblasts and hepatocyte-like cells, Ad-SOX17-transduced cells were differentiated according to our previously described method [13]. Our previous report demonstrated that transient HEX transduction efficiently generates hepatoblasts from human ESC- and iPSC-derived DE cells. The hepatic differentiation protocol used in this study is illustrated in Figure 3A. After the hepatic differentiation, the morphology of human ESCs transduced with Ad-SOX17 followed by Ad-HEX was gradually changed into a hepatocyte morphology: polygonal in shape with distinct round nuclei by day 18 (Figure 3B). We also




Figure 2. Efficient DE differentiation from human ESC- and iPSC-derived mesendoderm cells by SOX17 transduction. (A–D) Undifferentiated human ESCs (H9) and Activin A-induced human ESC-derived cells, which were cultured with the medium containing Activin A (100 ng/ml) for 0, 1, 2, 3, and 4 days, were transduced with 3,000 VP/cell of Ad-SOX17 for 1.5 h. Ad-SOX17-transduced cells were cultured with 100 ng/ml of Activin A, and the gene expression levels of (A) the DE markers (FOXA2, GSC, and GATA4) and anterior DE marker (HEX), (B) the pluripotent marker (NANOG), (C) the ExEn marker (SOX7), and (D) the mesoderm marker (FLK1) were examined by real-time RT-PCR on day 5 of differentiation. The horizontal axis represents the day on which the cells were transduced with Ad-SOX17. The expression levels of human ESCs on day 0 were defined 1.0. (E, F) After human ESCs were cultured with 100 ng/ml of Activin A for 3 days, human ESC-derived mesendoderm cells were transduced with Ad-LacZ or Ad-SOX17 and cultured until day 5. Ad-LacZ- or Ad-SOX17-transduced DE cells were subjected to immunostaining with anti-c-Kit, anti-CXCR4 (E) and anti-HEX antibodies (F) and then analyzed by flow cytometry. (G) After Ad-LacZ or Ad-SOX17 transduction, the DE differentiation efficacies of the human ES cell line (H9) and three human iPSC cell lines (201B7, Dotcom, and Tic) were compared at day 5 of differentiation. All data are represented as the means \pm SD ($n = 3$). doi:10.1371/journal.pone.0021780.g002

examined hepatic gene and protein expression levels on day18 of differentiation. For this purpose, we used a human ES cell line (H9) and three human iPSC cell lines (201B7, Dotcom, Tic). On day 18 of differentiation, the gene and protein expression analysis showed up-regulation of the hepatic markers albumin (ALB) [27], cytochrome P450 2D6 (CYP2D6), CYP3A4, and CYP7A1 [28] mRNA and ALB, CYP2D6, CYP3A4, CYP7A1, and cytokeratin (CK)18 proteins in both Ad-SOX17- and Ad-HEX-transduced cells transduced cells as compared with both Ad-LacZ- and Ad-HEX-transduced cells (Figures 4A and 4B). These results indicated that Ad-SOX17-transduced cells were more committed to the hepatic lineage than non-transduced cells.

Discussion

The directed differentiation from human ESCs and iPSCs is a useful model system for studying mammalian development as well as a powerful tool for regenerative medicine [29]. In the present study, we elucidated the bidirectional role of SOX17 on either ExEn or DE differentiation from human ESCs and iPSCs. We initially confirmed that initiation of SOX17 expression was consistent with the time period of PrE or mesendoderm cells formation (Figures S1 and S2). We speculated that stage-specific transient SOX17 transduction in PrE or mesendoderm could enhance ExEn or DE differentiation from human ESCs and iPSCs, respectively.




Figure 3. Hepatic Differentiation of Human ESC- and iPSC-Derived DE Cells Transduced with Ad-HEX. (A) The procedure for differentiation of human ESCs and iPSCs into hepatoblasts and hepatocyte-like cells is presented schematically. Both hESF-GRO and hESF-DIF medium were supplemented with 5 factors and 0.5 mg/ml fatty acid-free BSA, as described in the Materials and Methods section. (B) Sequential morphological changes (day 0–18) of human ESCs (H9) differentiated into hepatocyte-like cells via the DE cells and the hepatoblasts are shown. The scale bar represents 50 μ m.
doi:10.1371/journal.pone.0021780.g003


SOX17 transduction at the pluripotent stage promoted random differentiation giving heterogeneous populations containing both ExEn and DE cells were obtained (Figures 2A–2C). Qu et al. reported that SOX17 promotes random differentiation of mouse ESCs into PrE cells and DE cells *in vitro* [30], which is in consistent with the present study. Previously, Niakan et al. and Seguin et al. respectively demonstrated that ESCs could promote either ExEn or DE differentiation by stable SOX17 expression, respectively [10,12]. Although these discrepancies might be attributable to differences in the species used in the experiments (i.e., human versus mice), SOX17 might have distinct functions according to the appropriate differentiation stage. To elucidate these discrepancies, we examined the stage-specific roles of SOX17 in the present study, and found that human ESCs and iPSCs could differentiate into either ExEn or DE cells when SOX17 was overexpressed at the PrE or mesendoderm stage, respectively, but not when it was overexpressed at the pluripotent stage (Figures 1 and 2). This is because endogenous SOX17 is strongly expressed in the PrE and primitive streak tissues but only slightly expressed in the inner cell mass, our system might adequately reflect the early embryogenesis [14,31].

In ExEn differentiation from human ESCs, stage-specific SOX17 overexpression in human ESC-derived PrE cells promoted efficient ExEn differentiation and repressed trophectoderm differentiation (Figures 1A and 1B), although SOX17 transduction at the pluripotent stage did not induce the efficient differentiation

of ExEn cells. In our protocol, the stage-specific overexpression of SOX17 could elevate the efficacy of AFP-positive or SOX7-positive ExEn differentiation from human ESCs and iPSCs. The reason for the efficient ExEn differentiation by SOX17 transduction might be due to the fact that SOX17 lies downstream from GATA6 and directly regulates the expression of GATA4 and GATA6 [12]. Although it was previously been reported that Sox17 plays a substantial role in late-stage differentiation of ExEn cells *in vitro* [32], those reports utilized embryoid body formation, in which other types of cells, including endoderm, mesoderm, and ectoderm cells, might have influences on cellular differentiation. The present study showed the role of SOX17 in a homogeneous differentiation system by utilizing a mono-layer culture system.

In DE differentiation from human ESCs, we found that DE cells were efficiently differentiated from the human ESC-derived mesendoderm cells by stage-specific SOX17 overexpression (Figure 2). Therefore, we concluded that SOX17 plays a significant role in the differentiation of mesendoderm cells to DE cells. Although SOX17 overexpression before the formation of mesendoderm cells did not affect mesoderm differentiation, SOX17 transduction at the mesendoderm stage selectively promoted DE differentiation and repressed mesoderm differentiation (Figures 2A and 2D). These results show that SOX17 plays a crucial role in decision of DE differentiation from mesendoderm cells, as previous studies suggested [33,34]. Interestingly, SOX17 transduction at the pluripotent stage promoted not only DE

A



B




Figure 4. Characterization of hepatocyte-like cells from human ESC- and iPSC-derived DE cells. (A) The Ad-LacZ-transduced cells and Ad-SOX17-transduced cells were transduced with 3,000 VP/cell of Ad-HEX for 1.5 h on day 6. On day 18 of differentiation, the levels of expression of the hepatocyte markers (ALB, CYP2D6, CYP3A4, and CYP7A1) were examined by real-time RT-PCR in human ESC (H9)-derived hepatocyte-like cells and human iPSC (201B7, Dotcom, or Tic)-derived hepatocyte-like cells. The gene expression profiles of cells transduced with both Ad-SOX17 and Ad-HEX (black bar) were compared with those of cells transduced with both Ad-LacZ and Ad-HEX (gray bar). The expression level of primary human hepatocytes (PH, hatched bar), which were cultured 48 h after plating the cells, were defined as 1.0. All data are represented as the means \pm SD ($n=3$). (B) The expression of the hepatocyte markers ALB (green), CYP2D6 (red), CYP3A4 (red), CYP7A1 (red), and CK18 (green) was also examined by immunohistochemistry on day 18 of differentiation. Nuclei were counterstained with DAPI (blue). The scale bar represents 50 μ m.

differentiation but also ExEn differentiation even in the presence of Activin A (Figures 2A and 2C), demonstrating that transduction at an inappropriate stage of differentiation prevents directed differentiation. These results suggest that stage-specific SOX17 transduction mimicking the gene expression pattern in embryogenesis could selectively promote DE differentiation.

Another important finding about DE differentiation is that the protocol in the present study was sufficient for nearly homogeneous DE and anterior DE differentiation by mesendoderm stage-specific SOX17 overexpression; the differentiation efficacies of c-Kit/CXCR4-double-positive DE cells and HEX-positive anterior DE cells were approximately 70% and 54%, respectively (Figures 2E and 2F). The conventional differentiation protocols without gene transfer were not sufficient for homogenous DE and anterior DE differentiation; the differentiation efficacies of DE and anterior DE were approximately 30% and 10%, respectively [10,11,23]. One of the reasons for the efficient DE differentiation by SOX17 transduction might be the activation of the FOXA2 gene which could regulate many endoderm-associated genes [35]. Moreover, SOX17-transduced cells were more committed to the hepatic lineage (Figure 4). This might be because the number of HEX-positive anterior DE cell populations was increased by

SOX17 transduction. Recent studies have shown that the conditional expression of Sox17 in the pancreas at E12.5, when it is not normally expressed, is sufficient to promote biliary differentiation at the expense of endocrine cells [36]. Therefore, we reconfirmed that our protocol in which SOX17 was transiently transduced at the appropriate stage of differentiation was useful for DE and hepatic differentiation from human ESCs and iPSCs.

Using human iPSCs as well as human ESCs, we confirmed that stage-specific overexpression of SOX17 could promote directive differentiation of either ExEn or DE cells (Figures 1F, 2G, and 4A). Interestingly, a difference of DE and hepatic differentiation efficacy among human iPS cell lines was observed (Figures 1F and 2G). Therefore, it would be necessary to select a human iPS cell line that is suitable for hepatic differentiation in the case of medical applications, such as liver transplantation.

To control cellular differentiation mimicking embryogenesis, we employed Ad vectors, which are one of the most efficient transient gene delivery vehicles and have been widely used in both experimental studies and clinical trials [37]. Recently, we have also demonstrated that ectopic HEX expression by Ad vectors in human ESC-derived DE cells markedly enhances the hepatic differentiation [13]. Thus, Ad vector-mediated transient gene

transfer should be a powerful tool for regulating cellular differentiation.

In summary, the findings presented here demonstrate a stage-specific role of SOX17 in the ExEn and DE differentiation from human ESCs and iPSCs (Figure S8). Although previous reports showed that SOX17 overexpression in ESCs leads to differentiation of either ExEn or DE cells, we established a novel method to promote directive differentiation by SOX17 transduction. Because we utilized a stage-specific overexpression system, our findings provide further evidence that the lineage commitment in this method seems to reflect what is observed in embryonic development. In the present study, both human ESCs and iPSCs (3 lines) were used and all cell lines showed efficient ExEn or DE differentiation, indicating that our novel protocol is a powerful tool for efficient and cell line-independent endoderm differentiation. Moreover, the establishing methods for efficient hepatic differentiation by sequential SOX17 and HEX transduction would be useful for *in vitro* applications such as screening of pharmacological compounds as well as for regenerative therapy.

Materials and Methods

In vitro Differentiation

Before the initiation of cellular differentiation, the medium of human ESCs and iPSCs was exchanged for a defined serum-free medium hESF9 [38] and cultured as we previously reported. hESF9 consists of hESF-GRO medium (Cell Science & Technology Institute) supplemented with 5 factors (10 µg/ml human recombinant insulin, 5 µg/ml human apotransferrin, 10 µM 2-mercaptoethanol, 10 µM ethanolamine, and 10 µM sodium selenite), oleic acid conjugated with fatty acid free bovine albumin, 10 ng/ml FGF2, and 100 ng/ml heparin (all from Sigma).

To induce, ExEn cells, human ESCs and iPSCs were cultured for 5 days on a gelatin-coated plate in mouse embryonic conditioned-medium supplemented with 20 ng/ml BMP4 (R&D system) and 1% FCS (GIBCO-BRL).

The differentiation protocol for induction of DE cells, hepatoblasts, and hepatocyte-like cells was based on our previous report with some modifications [13]. Briefly, in DE differentiation, human ESCs and iPSCs were cultured for 5 days on a Matrigel (BD)-coated plate in hESF-DIF medium (Cell Science & Technology Institute) supplemented with the above-described 5 factors, 0.5 mg/ml BSA, and 100 ng/ml Activin A (R&D Systems). For induction of hepatoblasts, the DE cells were transduced with 3,000 VP/cell of Ad-HEX for 1.5 h and cultured in hESF-DIF (Cell Science & Technology Institute) medium supplemented with the above-described 5 factors, 0.5 mg/ml BSA, 10 ng/ml bone morphology protein 4 (BMP4) (R&D Systems), and 10 ng/ml FGF4 (R&D systems). In hepatic differentiation, the cells were cultured in hepatocyte culture medium (HCM) supplemented with SingleQuots (Lonza), 10 ng/ml hepatocyte growth factor (HGF) (R&D Systems), 10 ng/ml Oncostatin M (OsM) (R&D Systems), and 10^{-7} M dexamethasone (DEX) (Sigma).

Human ESC and iPSC Culture

A human ES cell line, H9 (WiCell Research Institute), was maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts (Millipore) with Repro Stem (Repro CELL), supplemented with 5 ng/ml fibroblast growth factor 2 (FGF2) (Sigma). Human ESCs were dissociated with 0.1 mg/ml dispase (Roche Diagnostics) into small clumps, and subcultured every 4 or 5 days. Two human iPS cell lines generated from the human embryonic lung fibroblast cell line MCR5 were provided from the

JCRB Cell Bank (Tic, JCRB Number: JCRB1331; and Dotcom, JCRB Number: JCRB1327) [39,40]. These human iPS cell lines were maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts with iPSellon (Cardio), supplemented with 10 ng/ml FGF2. Another human iPS cell line, 201B7, generated from human dermal fibroblasts (HDF) was kindly provided by Dr. S. Yamanaka (Kyoto University) [6]. The human iPS cell line 201B7 was maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts with Repro Stem (Repro CELL), supplemented with 5 ng/ml FGF2 (Sigma). Human iPSCs were dissociated with 0.1 mg/ml dispase (Roche Diagnostics) into small clumps, and subcultured every 5 or 6 days.

Adenovirus (Ad) Vectors

Ad vectors were constructed by an improved *in vitro* ligation method [41,42]. The human SOX17 gene (accession number NM_022454) was amplified by PCR using primers designed to incorporate the 5' BamHI and 3' XbaI restriction enzyme sites: Fwd 5'-gcaggatccagcgcctatgagcagcccg-3' and Rev 5'-cttctagatcaggacacctgtcacacgtc-3'. The human SOX17 gene was inserted into pcDNA3 (Invitrogen), resulting in pcDNA-SOX17, and then the human SOX17 gene was inserted into pHMEF5 [15], which contains the human EF-1α promoter, resulting in pHMEF-SOX17. The pHMEF-SOX17 was digested with I-CeuI/PI-SceI and ligated into I-CeuI/PI-SceI-digested pAdHM41-K7 [16], resulting in pAd-SOX17. The human elongation factor-1α (EF-1α) promoter-driven LacZ- or HEX-expressing Ad vectors, Ad-LacZ or Ad-HEX, were constructed previously. [13,43]. Ad-SOX17, Ad-HEX, and Ad-LacZ, which contain a stretch of lysine residue (K7) peptides in the C-terminal region of the fiber knob for more efficient transduction of human ESCs, iPSCs, and DE cells, were generated and purified as described previously [13,15,43]. The vector particle (VP) titer was determined by using a spectrophotometric method [44].

Flow Cytometry

Single-cell suspensions of human ESCs, iPSCs, and their derivatives were fixed with methanol at 4°C for 20 min, then incubated with the primary antibody, followed by the secondary antibody. Flow cytometry analysis was performed using a FACS LSR Fortessa flow cytometer (Becton Dickinson).

RNA Isolation and Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Total RNA was isolated from human ESCs, iPSCs, and their derivatives using ISOGENE (Nippon Gene) according to the manufacturer's instructions. Primary human hepatocytes were purchased from CellDirect. cDNA was synthesized using 500 ng of total RNA with a Superscript VILO cDNA synthesis kit (Invitrogen). Real-time RT-PCR was performed with Taqman gene expression assays (Applied Biosystems) or SYBR Premix Ex Taq (TaKaRa) using an ABI PRISM 7000 Sequence Detector (Applied Biosystems). Relative quantification was performed against a standard curve and the values were normalized against the input determined for the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primer sequences used in this study are described in Table S1.

Immunohistochemistry

The cells were fixed with methanol or 4% PFA. After blocking with PBS containing 2% BSA and 0.2% Triton X-100 (Sigma), the cells were incubated with primary antibody at 4°C for 16 h, followed by incubation with a secondary antibody that was labeled

with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen) at room temperature for 1 h. All the antibodies are listed in Table S2.

Crystal Violet Staining

The human ESC-derived cells that had adhered to the wells were stained with 200 μ l of 0.3% crystal violet solution at room temperature for 15 min. Excess crystal violet was then removed and the wells were washed three times. Fixed crystal violet was solubilized in 200 μ l of 100% ethanol at room temperature for 15 min. Cell viability was estimated by measuring the absorbance at 595 nm of each well using a microtiter plate reader (Sunrise, Tecan).

LacZ Assay

The human ESC- and iPSC-derived cells were transduced with Ad-LacZ at 3,000 VP/cell for 1.5 h. After culturing for the indicated number of days, 5-bromo-4-chloro-3-indolyl β -D-galactopyranoside (X-Gal) staining was performed as described previously [15].

Supporting Information

Table S1 List of Taqman probes and primers used in this study.
(DOC)

Table S2 List of antibodies used in this study.
(DOC)

Figure S1 PrE cells formation from human ESCs on day 1 of differentiation. (A) The procedure for differentiation of human ESCs and iPSCs to ExEn cells by treatment with BMP4 (20 ng/ml) is presented schematically. (B) Human ESCs (H9) were morphologically changed during ExEn differentiation; when human ESCs were cultured with the medium containing BMP4 (20 ng/ml) for 5 days, the cells began to show flattened epithelial morphology. The scale bar represents 50 μ m. (C–E) The tTemporal protein expression analysis during ExEn differentiation was performed by immunohistochemistry. The PrE markers COUP-TF1 [21] (red), SOX17 [14] (red), and SOX7 [14] (red) were detected on day 1. In contrast to the PS markers, the expression of the DE marker GSC [22] (red) was not detected and the level of the pluripotent marker NANOG (green) declined between day 0 and day 1. Nuclei were counterstained with DAPI (blue). The scale bar represents 50 μ m.
(PDF)

Figure S2 Mesendoderm cells formation from human ESCs on day 3 of differentiation. (A) The procedure for differentiation of human ESCs and iPSCs to DE cells by treatment with Activin A (100 ng/ml) is presented schematically. hESF-GRO medium was supplemented with 5 factors and 0.5 mg/ml fatty acid free BSA, as described in the Materials and Methods. (B) Human ESCs (H9) were morphologically changed during DE differentiation; when human ESCs were cultured with the medium containing Activin A (100 ng/ml) for 5 days, the morphology of the cells began to show visible cell-cell boundaries. The scale bar represents 50 μ m. (C–E) The tTemporal protein expression analysis during DE differentiation was performed by immunohistochemistry. The anterior PS markers FOXA2 [21] (red), GSC [22] (red), and SOX17 [14] (red) were adequately detected on day 3. The PS marker T [45] (red) was detected until day 3. In contrast to the PS markers, the expression of the pluripotent marker NANOG [24] (green) declined between day 2 and day 3. Nuclei were counterstained with DAPI (blue). The scale bar represents 50 μ m.
(PDF)

Figure S3 Overexpression of SOX17 mRNA in human ESC (H9)-derived PS cells by Ad-SOX17 transduction. Human ESC-derived PS cells (day 1) were transduced with 3,000VP/cell of Ad-SOX17 for 1.5 h. On day 3 of differentiation, real-time RT-PCR analysis of the SOX17 expression was performed in Ad-LacZ-transduced cells and Ad-SOX17-transduced cells. On the y axis, the expression levels of undifferentiated human ESCs on day 0 were taken defined as 1.0. All data are represented as the means \pm SD ($n = 3$).
(PDF)

Figure S4 Efficient transduction in Activin A-induced human ESC (H9)-derived cells by using a fiber-modified Ad vector containing the EF-1 α promoter. Undifferentiated human ESCs and Activin A-induced human ESC-derived cells, which were cultured with the medium containing Activin A (100 ng/ml) for 0, 1, 2, 3, and 4 days, were transduced with 3,000 vector particles (VP)/cell of Ad-LacZ for 1.5 h. The day after transduction, X-gal staining was performed. The scale bar represents 100 μ m. Similar results were obtained in two independent experiments.
(PDF)

Figure S5 Optimization of the time period for Ad-SOX17 transduction to promote DE differentiation from human iPSCs (Tic). Undifferentiated human iPSCs and Activin A-induced human iPSC-derived cells, which were cultured with the medium containing Activin A (100 ng/ml) for 0, 1, 2, 3, and 4 days, were transduced with 3,000 VP/cell of Ad-SOX17 for 1.5 h. Ad-SOX17-transduced cells were cultured with Activin A (100 ng/ml) until day 5, and then real-time RT-PCR analysis was performed. The horizontal axis represents the day on which the cells were transduced with Ad-SOX17. On the y axis, the expression levels of undifferentiated cells on day 0 were taken defined as 1.0. All data are represented as the means \pm SD ($n = 3$).
(PDF)

Figure S6 Time course of LacZ expression in human ESC (H9)-derived mesendoderm cells transduced with Ad-LacZ. The hHuman ESC-derived mesendoderm cells (day 3) were transduced with 3,000 VP/cell of Ad-LacZ for 1.5 h. On days 4, 5, 6, 8, and 10, X-gal staining was performed. Note that human ESC-derived cells were passaged on day 5. The scale bar represents 100 μ m. Similar results were obtained in two independent experiments.
(PDF)

Figure S7 Optimization of the time period for Ad-SOX17 transduction into Activin A-induced human ESC (H9)-derived cells. Undifferentiated human ESCs and Activin A-induced hESC-derived cells, which were cultured with the medium containing Activin A (100 ng/ml) for 0, 1, 2, 3, and 4 days, were transduced with 3,000 VP/cell of Ad-LacZ or Ad-SOX17 for 1.5 h. Ad-SOX17-transduced cells were cultured with Activin A (100 ng/ml) until day 5, then the cell viability was evaluated with crystal violet staining. The horizontal axis represents the day on which the cells were transduced with Ad-SOX17. On the y axis, the level of non-transduced cells was taken defined as 1.0. All data are represented as the means \pm SD ($n = 3$).
(PDF)

Figure S8 Model of differentiation of human ESCs and iPSCs into ExEn and DE cells by stage-specific SOX17 transduction. The ExEn and DE differentiation process is divided into at least two stages. In the first stage, human ESCs differentiate into either PrE cells by treatment with BMP4 (20 ng/ml) or mesendoderm cells by treatment with Activin A (100 ng/ml).

ml). In the second stage, SOX17 promotes the further differentiation of each precursor cell into ExEn and DE cells, respectively. We have demonstrated that the efficient differentiation of these two distinct endoderm lineages is accomplished by stage-specific SOX17 transduction.

(PDF)

Acknowledgments

We thank Hiroko Matsumura and Misae Nishijima for their excellent technical support. We thank Mr. David Bennett and Ms. Ong Tyng Tyng for critical reading of the manuscript.

References

- Enders AC, Given RL, Schlafke S (1978) Differentiation and migration of endoderm in the rat and mouse at implantation. *Anat Rec* 190: 65–77.
- Gardner RL (1983) Origin and differentiation of extraembryonic tissues in the mouse. *Int Rev Exp Pathol* 24: 63–133.
- Grapin-Botton A, Constam D (2007) Evolution of the mechanisms and molecular control of endoderm formation. *Mech Dev* 124: 253–278.
- Tam PP, Kanai-Azuma M, Kanai Y (2003) Early endoderm development in vertebrates: lineage differentiation and morphogenetic function. *Curr Opin Genet Dev* 13: 393–400.
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. (1998) Embryonic stem cell lines derived from human blastocysts. *Science* 282: 1145–1147.
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861–872.
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318: 1917–1920.
- Xu RH, Chen X, Li DS, Li R, Addicks GC, et al. (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. *Nat Biotechnol* 20: 1261–1264.
- Pera MF, Andrade J, Houssami S, Reubinoff B, Trounson A, et al. (2004) Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. *J Cell Sci* 117: 1269–1280.
- Seguin CA, Draper JS, Nagy A, Rossant J (2008) Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. *Cell Stem Cell* 3: 182–195.
- Gouon-Evans V, Boussemaert L, Gadue P, Nierhoff D, Koehler CI, et al. (2006) BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. *Nat Biotechnol* 24: 1402–1411.
- Niakan KK, Ji H, Machr R, Vokes SA, Rodolfa KT, et al. (2010) Sox17 promotes differentiation in mouse embryonic stem cells by directly regulating extraembryonic gene expression and indirectly antagonizing self-renewal. *Genes Dev* 24: 312–326.
- Inamura M, Kawabata K, Takayama K, Tashiro K, Sakurai F, et al. (2011) Efficient Generation of Hepatoblasts From Human ES Cells and iPS Cells by Transient Overexpression of Homeobox Gene HEX. *Mol Ther* 19: 400–407.
- Kanai-Azuma M, Kanai Y, Gad JM, Tajima Y, Taya C, et al. (2002) Depletion of definitive gut endoderm in Sox17-null mutant mice. *Development* 129: 2367–2379.
- Kawabata K, Sakurai F, Yamaguchi T, Hayakawa T, Mizuguchi H (2005) Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. *Mol Ther* 12: 547–554.
- Koizumi N, Mizuguchi H, Utochuchi N, Watanabe Y, Hayakawa T (2003) Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. *J Gene Med* 5: 267–276.
- Fujikura J, Yamato E, Yonemura S, Hosoda K, Masui S, et al. (2002) Differentiation of embryonic stem cells is induced by GATA factors. *Genes Dev* 16: 784–789.
- Koutsourakis M, Langeveld A, Patient R, Beddington R, Grosveld F (1999) The transcription factor GATA6 is essential for early extraembryonic development. *Development* 126: 723–732.
- Morrissey EE, Tang Z, Sigrist K, Lu MM, Jiang F, et al. (1998) GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. *Genes Dev* 12: 3579–3590.
- Kunath T, Strumpf D, Rossant J (2004) Early trophoblast determination and stem cell maintenance in the mouse—a review. *Placenta* 25 Suppl A: S32–38.
- Sasaki H, Hogan BL (1993) Differential expression of multiple fork head related genes during gastrulation and axial pattern formation in the mouse embryo. *Development* 118: 47–59.
- Blum M, Gaunt SJ, Cho KW, Steinbeisser H, Blumberg B, et al. (1992) Gastrulation in the mouse: the role of the homeobox gene goosecoid. *Cell* 69: 1097–1106.
- Morrison GM, Oikonomopoulou I, Migueles RP, Soneji S, Livigni A, et al. (2008) Anterior definitive endoderm from ESCs reveals a role for FGF signaling. *Cell Stem Cell* 3: 402–415.
- Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, et al. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. *Cell* 113: 631–642.
- Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* 376: 62–66.
- D'Amour KA, Agulnick AD, Eliazar S, Kelly OG, Kroon E, et al. (2005) Efficient differentiation of human embryonic stem cells to definitive endoderm. *Nat Biotechnol* 23: 1534–1541.
- Shiojiri N (1984) The origin of intrahepatic bile duct cells in the mouse. *J Embryol Exp Morphol* 79: 25–39.
- Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. *Trends Pharmacol Sci* 20: 342–349.
- Murry CE, Keller G (2008) Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. *Cell* 132: 661–680.
- Qu XB, Pan J, Zhang C, Huang SY (2008) Sox17 facilitates the differentiation of mouse embryonic stem cells into primitive and definitive endoderm in vitro. *Dev Growth Differ* 50: 585–593.
- Sherwood RI, Jitiani C, Cleaver O, Shaywitz DA, Lamenzo JO, et al. (2007) Prospective isolation and global gene expression analysis of definitive and visceral endoderm. *Dev Biol* 304: 541–555.
- Shimoda M, Kanai-Azuma M, Hara K, Miyazaki S, Kanai Y, et al. (2007) Sox17 plays a substantial role in late-stage differentiation of the extraembryonic endoderm in vitro. *J Cell Sci* 120: 3859–3869.
- Yasunaga M, Tada S, Torikai-Nishikawa S, Nakano Y, Okada M, et al. (2005) Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells. *Nat Biotechnol* 23: 1542–1550.
- Gadue P, Huber TL, Paddison PJ, Keller GM (2006) Wnt and TGF-beta signaling are required for the induction of an in vitro model of primitive streak formation using embryonic stem cells. *Proc Natl Acad Sci U S A* 103: 16806–16811.
- Levinson-Dushnik M, Benvenisty N (1997) Involvement of hepatocyte nuclear factor 3 in endoderm differentiation of embryonic stem cells. *Mol Cell Biol* 17: 3817–3822.
- Spence JR, Lange AW, Lin SC, Kaestner KH, Lowy AM, et al. (2009) Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. *Dev Cell* 17: 62–74.
- Mizuguchi H, Hayakawa T (2004) Targeted adenovirus vectors. *Hum Gene Ther* 15: 1034–1044.
- Furue MK, Na J, Jackson JP, Okamoto T, Jones M, et al. (2008) Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. *Proc Natl Acad Sci U S A* 105: 13409–13414.
- Makino H, Toyoda M, Matsumoto K, Saito H, Nishino K, et al. (2009) Mesenchymal to embryonic incomplete transition of human cells by chimeric OCT4/3 (POU5F1) with physiological co-activator EWS. *Exp Cell Res* 315: 2727–2740.
- Nagata S, Toyoda M, Yamaguchi S, Hirano K, Makino H, et al. (2009) Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells. *Genes Cells* 14: 1395–1404.
- Mizuguchi H, Kay MA (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. *Hum Gene Ther* 9: 2577–2583.
- Mizuguchi H, Kay MA (1999) A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. *Hum Gene Ther* 10: 2013–2017.
- Tashiro K, Kawabata K, Sakurai H, Kurachi S, Sakurai F, et al. (2008) Efficient adenovirus vector-mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation. *J Gene Med* 10: 498–507.
- Maizel JV, Jr., White DO, Scharff MD (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* 36: 115–125.
- Wilkinson DG, Bhatt S, Herrmann BG (1990) Expression pattern of the mouse T gene and its role in mesoderm formation. *Nature* 343: 657–659.

Author Contributions

Conceived and designed the experiments: K. Takayama MI K. Kawabata MFK HM. Performed the experiments: K. Takayama MI K. Tashiro. Analyzed the data: K. Takayama MI K. Kawabata K. Tashiro K. Katayama FS HM. Contributed reagents/materials/analysis tools: K. Kawabata K. Katayama FS TH MFK HM. Wrote the paper: K. Takayama K. Kawabata HM.

Enhanced Safety Profiles of the Telomerase-Specific Replication-Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences

Kumiko Sugio^{1,3}, Fuminori Sakurai^{1,3}, Kazufumi Katayama¹, Katsuhisa Tashiro³, Hayato Matsui^{1,3}, Kenji Kawabata^{2,3}, Atsushi Kawase⁴, Masahiro Iwaki⁴, Takao Hayakawa⁵, Toshiyoshi Fujiwara⁶, and Hiroyuki Mizuguchi^{1,3}

Abstract

Purpose: Oncolytic adenoviruses (Ad) have been actively pursued as potential agents for cancer treatment. Among the various types of oncolytic Ads, the telomerase-specific replication-competent Ad (TRAD), which possesses an *E1* gene expression cassette driven by the human telomerase reverse transcriptase promoter, has shown promising results in human clinical trials; however, the *E1* gene is also slightly expressed in normal cells, leading to replication of TRAD and cellular toxicity in normal cells.

Experimental Design: To overcome this problem, we utilized a microRNA (miRNA)-regulated gene expression system. Four copies of complementary sequences for miR-143, -145, -199a, or let-7a, which have been reported to be exclusively downregulated in tumor cells, were incorporated into the 3'-untranslated region of the *E1* gene expression cassette.

Results: Among the TRAD variants (herein called TRADs) constructed, TRADs containing the sequences complementary to miR-143, -145, or -199a showed efficient oncolytic activity comparable to the parental TRAD in the tumor cells. On the other hand, replication of the TRADs containing the miRNA complementary sequences was at most 1,000-fold suppressed in the normal cells, including primary normal cells. In addition, to suppress the replication of the TRADs in hepatocytes as well as other normal cells, we constructed a TRAD containing 2 distinct complementary sequences for miR-199a and liver-specific miR-122a (TRAD-122a/199aT). TRAD-122a/199aT exhibited more than 10-fold reduction in viral replication in all the normal cells examined, including primary hepatocytes.

Conclusions: This study showed that oncolytic Ads containing the sequences complementary to normal cell-specific miRNAs showed significantly improved safety profiles without altering tumor cell lysis activity. *Clin Cancer Res*; 17(9); 2807–18. ©2011 AACR.

Introduction

Oncolytic adenoviruses (Ad) are genetically engineered Ads which can kill tumor cells by tumor cell-specific replication (1, 2). Several clinical trials using oncolytic Ads have been carried out, and promising results have been reported (3–5). Various types of oncolytic Ads have been developed, and can be mainly classified into 2 groups. One type of oncolytic Ads show tumor-selective replication via deletion of certain genes, such as the *E1B-55K* gene, which are dispensable for the replication of Ads in tumor cells. The other type of oncolytic Ads possess an *E1* gene expression cassette driven by tumor-specific promoters. Various types of tumor-specific promoters are used in oncolytic Ads, including the α -fetoprotein promoter (6), prostate-specific antigen promoter (7), osteocalcin promoters (8), and cyclooxygenase-2 promoter (9).

Among these oncolytic Ads possessing tumor-specific promoters, the telomerase-specific replication-competent

Authors' Affiliations: Departments of ¹Biochemistry and Molecular Biology and ²Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University; ³Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation; ⁴Department of Pharmacy, School of Pharmacy, ⁵Pharmaceutical Research and Technology Institute, Kinki University, Osaka; and ⁶Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Fuminori Sakurai, Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan. Phone: 81-6-6879-8188; Fax: 81-6-6879-8186; E-mail: sakurai@phs.osaka-u.ac.jp or Hiroyuki Mizuguchi, Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. Phone: 81-6-6879-8185; Fax: 81-6-6879-8186; E-mail: mizuguch@phs.osaka-u.ac.jp

doi: 10.1158/1078-0432.CCR-10-2008

©2011 American Association for Cancer Research.

Translational Relevance

Oncolytic adenoviruses (Ad) are promising anticancer agents and have been used in human clinical trials. However, though a lesser extent than in tumor cells, some oncolytic Ads also replicate in normal human cells, resulting in unexpected toxicity. In this study, we included a microRNA (miRNA)-regulated posttranscriptional detargeting system into a telomerase-specific replication-competent Ad (TRAD), which has been used in clinical trials. Complementary sequences for miR-143, -145, and -199a, which have been shown to be exclusively downregulated in tumor cells, were inserted into the *E1* gene expression cassette. The TRAD containing these miRNA complementary sequences exhibited significantly reduced replication in normal cells (up to 1,000-fold reductions), including human primary cells, and comparable tumor cell lysis activity to the conventional TRAD. These results indicate that an miRNA-regulated posttranscriptional detargeting system offers a potential strategy to reduce the replication of TRAD in normal cells without altering tumor cell lysis activity, and makes it possible to increase the injected doses, leading to enhanced antitumor effects.

Ad (TRAD; also known as Telomelysin), which has an *E1* gene expression cassette driven by the human telomerase reverse transcriptase (hTERT) promoter, is one of the most promising oncolytic Ads (10, 11). A variety of tumor cells express telomerase and most normal cells do not, leading to tumor-selective efficient replication of TRAD. A phase I clinical trial using TRAD has already been carried out, and antitumor effects were shown in several patients (3). Combined therapy using anticancer agents and TRAD also has been shown to provide enhanced antitumor effects compared with either treatment alone (12). Another advantage of TRAD is that TRAD exerts antitumor effects on distant, uninjected tumors following intratumoral administration. TRAD efficiently replicates in the injected tumors and is disseminated from the injected tumors into the systemic circulation, resulting in infection of distant tumors with TRAD (11, 13). This property of TRAD has made it possible to visualize lymph node metastasis by inclusion of the green fluorescence protein (GFP)-expression cassette into TRAD (14). However, these properties have led to the concern that TRAD also infects normal cells throughout the body after their dissemination from the injected tumors. Some oncolytic Ads, including TRAD, replicate to some extent in normal human cells although tumor-specific promoters are used probably because low levels of *E1A* expression can sufficiently support the replication of Ads (15). Previous studies have shown a more than 100-fold increase in Ad genome copy numbers in human primary fibroblasts 3 days after infection with TRAD (10, 11). Replication of TRAD in normal human cells might lead to unexpected cellular toxicity, therefore, in addition to a tumor-specific promoter, a system which can prevent

the replication of TRAD in normal human cells should be incorporated into TRAD.

To achieve this goal, we utilized a microRNA (miRNA)-regulated gene expression system. MiRNAs are small non-coding RNAs of approximately 22-nt in length, and are endogenously expressed. MiRNAs bind to imperfectly complementary sequences in the 3'-untranslated region (UTR) of the target mRNA leading to the suppression of gene expression via posttranscriptional regulation. More than 800 miRNAs have been identified and have been shown to be expressed in tissue- and cell-type-specific patterns. Furthermore, recent studies have shown that several miRNAs, including miR-143, -145, and let-7, are specifically downregulated in tumor cells, compared with normal cells (16–20). Thus we hypothesized that incorporation of the complementary sequences for miRNAs selectively downregulated in tumor cells into the *E1* expression cassette would prevent the replication of TRADs in normal human cells without altering the antitumor effects.

In the present study, miR-143, -145, -199a, and let-7a were selected as the miRNAs exclusively downregulated in tumor cells. Four copies of sequences perfectly complementary to these miRNAs were inserted into the 3'-UTR of the *E1* gene expression cassette in TRADs. TRADs containing the target sequences for miR-143, -145, or -199a exhibited not only efficient oncolytic activities comparable to the parental TRAD, but also significantly reduced levels of replication (up to 1,000-fold reductions) in normal cells, including human primary cells. Furthermore, insertion of sequences complementary to liver-specific miR-122a into the *E1* gene expression cassette, in addition to the miR-199a target sequences, resulted in a decrease in virus replication in primary hepatocytes as well as other primary cells.

Materials and Methods

Cells

A549 (a human non-small cell lung cancer cell line), HepG2 (a human hepatocellular carcinoma cell line), and 293 cells (a transformed embryonic kidney cell line) were cultured in Dulbecco's modified Eagle's Medium containing 10% fetal bovine serum (FBS) and antibiotics. HT29 (a human colorectal cancer cell line) and WI38 cells (a normal human lung diploid fibroblast) were cultured in Minimum Essential Medium containing 10% FBS and antibiotics. H1299 cells (a human non-small cell lung cancer cell line) were cultured in RPMI1640 containing 10% FBS and antibiotics. These cell lines were obtained from the cell banks, including the Japanese Collection of Research Bioresources (JCRB) cell bank. The normal human lung fibroblasts (NHLE), normal human prostate stromal cells (PrSC), normal human small airway epithelial cells (SAEC), and normal human hepatocytes (Nhep; Lonza) were cultured in the medium recommended by the manufacturer.

Construction of TRADs

All TRADs were prepared by means of an improved *in vitro* ligation method described previously (21–23). hTERT

promoter-driving *E1* gene-expressing shuttle plasmids having multiple tandem copies of sequences perfectly complementary to miRNAs in the 3'-UTR of the *E1* gene expression cassette were constructed as described below. A *KpnI*/*AflIII* fragment of pHCMV5 (22) was ligated with oligonucleotides miR-143T-S1 and miR-143T-AS1, which contain miR-143 complementary sequences, resulting in pHCMV5-143T-1. The sequences of the oligonucleotides are shown in Supplementary Table S1. Next, a *PacI*/*AflIII* fragment of pHCMV5-143T-1 was ligated with oligonucleotides miR-143T-S2 and miR-143T-AS2. The resulting plasmid, pHCMV5-143T, was digested with *I-CeuI* after digestion with *NheI* followed by *Klenow* treatment, and then ligated with the *I-CeuI*/*PmeI* fragment of pSh-hAIB (10), in which the *E1A* and *E1B* genes linked with an internal ribosomal entry site (IRES) are located downstream of the hTERT promoter, creating pSh-AIB-143T. For the construction of vector plasmids for TRADs, *I-CeuI*/*Pi-SceI*-digested pSh-AIB-143T was ligated with the *I-CeuI*/*Pi-SceI*-digested pAdHM3 (21), resulting in pAdHM3-AIB-143T. To generate TRADs, pAdHM3-AIB-143T was digested with *PacI* and was transfected into 293 cells using Superfect transfection reagent (Qiagen). All TRADs were propagated in 293 cells, purified by 2 rounds of cesium chloride gradient ultracentrifugation, dialyzed, and stored at -80°C . TRADs containing other miRNA complementary sequences were similarly constructed using the corresponding oligonucleotides (Supplementary Table S1). The parental TRAD was similarly prepared using pSh-AIB and pAdHM3. The virus particles (VP) and biological titers were determined by a spectrophotometrical method (24) and by using an Adeno-X rapid titer kit (Clontech), respectively. The ratio of particle-to-biological titer was between 6 and 9 for each TRAD used in this study.

Determination of miRNA expression levels in human normal and tumor cells

Total RNA, including miRNAs, was isolated from cells using Isogen (Nippon Gene). After quantification of the RNA concentration, miRNA levels were determined using a TaqMan MiRNA reverse transcription kit, TaqMan miRNA assay kit, and ABI Prism 7000 system (Applied Biosystems). Amplification of U6 served as an endogenous control to normalize the miRNA expression data.

Infection with TRADs

Cells were seeded into 24-well plates at 5×10^4 cells/well. On the following day, cells were infected with TRADs at a multiplicity of infection (MOI) of 0.4 or 2 (for cancer cell lines), or of 10 (for normal cells), for 2 hours. Following incubation for 3 (for cancer cell lines) or 5 days (for normal cells), total DNA, including viral genomic DNA, was isolated from the cells using a DNeasy Blood & Tissue Kit (Qiagen). After isolation, the Ad genomic DNA contents were quantified using an ABI Prism 7000 system (Applied Biosystems) as previously described (25). The Ad genome copy numbers were normalized by the copy numbers of

glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). Cell viability was also examined by crystal violet staining and Alamar blue assay at the indicated time points. To examine the miRNA-specific suppression of TRAD replication in normal human cells, 50 nmol/L of 2'-O-methylated antisense oligonucleotide complementary to miR-143 or miR-199a (Gene Design Inc.) was transfected into normal cells using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, the cells were infected with TRADs and replication of TRADs was evaluated as described above.

Real-time reverse transcriptase PCR analysis for *E1A* gene expression

Cells were seeded as described above and were infected with TRADs at an MOI of 2 (for cancer cells) or 10 (for normal cells) for 1.5 hours. After a 24 hour-incubation, total RNA was isolated, and reverse transcription reaction was carried out using a SuperScript II First-Strand Synthesis System (Invitrogen). *E1A* mRNA levels were determined with the *E1A*-specific primers and probe using an ABI prism 7000 system (26). The *E1A* mRNA levels were normalized by the GAPDH mRNA levels.

Statistical analysis

Statistical significance ($P < 0.05$) was determined using Student's *t* test. Data are presented as means \pm SD.

Results

Replication of the conventional TRAD in normal human cells

First, to examine replication of the conventional TRAD in normal human cells, WI38 cells, which are human embryonic lung fibroblasts, were infected with the conventional TRAD at an MOI of 2 or 10 (Fig. 1). The conventional TRAD did not highly replicate in WI38 cells at an MOI of 2; however, an almost 500-fold increase in the Ad genome




Figure 1. Replication of the conventional TRAD in WI38 cells. WI38 cells were infected with the conventional TRAD at an MOI of 2 or 10 for 2 hours. At the indicated time points, the copy numbers of the Ad genome and *GAPDH* gene were determined by real-time PCR. The ratio of the copy number of the Ad genome to that of *GAPDH* was normalized by the data on day 0. The data are shown as the means \pm SD ($n = 3$).




Figure 2. MiRNA expression levels in the human normal (solid bar) and tumor cells (hatched bar). MiRNA expression was determined by real-time RT-PCR. The ratio of miRNA to U6 expression levels was normalized by the data of W38 cells. The data are shown as the means \pm SD ($n = 3$). N.D., not detected.

was found 3 days after infection at an MOI of 10. These data indicate that the conventional TRAD replicates in normal human cells at a high MOI, even though tumor-specific hTERT promoters are used for the *E1* gene expression.

MiRNA expression levels in human tumor and normal cells

To examine the expression levels of miR-143, -145, -199a, and let-7a in the human normal and tumor cells, reverse transcriptase PCR (RT-PCR) analysis was carried out. Several studies have shown that these miRNAs are downregulated in various types of tumor cells isolated from cancer patients, compared with the corresponding normal tissues (16–18, 27). The expression levels of miR-143, -145, and -199a in the tumor cells were approximately 2- to 100-fold lower than those in the normal cells, although SAECs expression levels of miR-143, -145, and -199a were comparable or lower than those in the tumor cells (Fig. 2). In particular, a large reduction was found for miR-199a expression in all tumor cells, compared with the normal cells. On the other hand, the expression levels of let-7a in HT29 and H1299 cells were higher than those in the normal cells, although HepG2 cells expressed lower levels of let-7a than the normal cells. The absolute amounts of let-7a were more than 10-fold higher than those of the other miRNAs in all tumor and normal cells, except for NHLF, NHep, and HepG2 cells (data not shown).

Development of TRADs carrying an miRNA-regulated *E1* gene expression system

Next, to develop TRADs carrying a miRNA-regulated *E1* gene expression cassette (TRAD-miRT), we incorporated 4

copies of the perfectly complementary sequences for miR-143, -145, -199a, or let-7a into the 3'-UTR of the *E1* gene expression cassette (Fig. 3A). In TRADs, the *E1A* gene was connected with the *E1B* gene via IRES. We found that the expression of both the first and second gene in the IRES-containing expression cassette was suppressed in an miRNA-dependent manner by insertion of the miR-122a complementary sequences into the region downstream of the second gene in miR-122a-expressing Huh-7 cells, not in HepG2 cells, which express a low level of miR-122a (Supplementary Fig. S1), although it remains controversial whether miRNA-mediated posttranscriptional regulation can occur in an IRES-containing expression cassette (28–30). All TRADs were efficiently grown in normal 293 cells, and the ratios of infectious titers to physical titers were comparable among all the TRADs, including the parental TRAD.

Tumor cell lysis activity and replication of TRAD-miRT in tumor cells

To examine whether or not the inclusion of the sequences complementary to the miRNAs downregulated in tumor cells would inhibit the tumor cell lysis activity of TRADs, the viability of tumor cells was evaluated after infection with the TRADs. Almost all tumor cells were lysed by TRAD-143T, -145T, and -199aT at 3 days after infection, although cell lysis by TRAD-let7aT was largely inhibited (Fig. 3B). Furthermore, time-course studies of cell viability showed that TRAD-143T, -145T, and -199aT exhibited cytopathic efficacies comparable to that of the parental TRAD in the tumor cells at an MOI of 0.4 (Fig. 3C). Similar results were obtained at an MOI of 2 (data not shown).

We next examined the replication ability of the TRADs in the tumor cells by determining the viral genome copy numbers. TRAD-143T, -145T, and -199aT efficiently replicated in the tumor cells, and the viral genome copy numbers of TRAD-143T, -145T, and -199aT in the tumor cells were more than 500-fold higher than those in the normal cells (data not shown). In addition, TRAD-143T, -145T, and -199aT exhibited viral genome copy numbers similar to that of the conventional TRAD in all tumor cells (Fig. 3D). All TRADs except for TRAD-let7aT also expressed similar levels of E1A mRNA (Fig. 3E). In contrast, insertion of let-7a complementary sequences largely inhibited the replication in all tumor cells. The E1A mRNA level was also reduced by 42% in H1299 cells infected with TRAD-let7aT. Inefficient replication of TRAD-let7aT in the tumor cells corresponded to the low cytopathic effects described above. These results indicate that TRADs containing the complementary sequences for miR-143, -145, or -199a exhibit efficient E1 gene expression in the tumor cells and tumor cell lysis activity comparable to those of the conventional TRAD.

Reduced replication of TRAD-miRT in normal cells

To examine whether replication of TRADs in normal cells is suppressed by incorporation of the sequences complementary to the miRNAs downregulated in tumor cells, normal human cells were infected with the TRADs. The virus genome copy numbers of TRAD-143T, -145T, and -199aT were 5- to 1,000-fold reduced, compared with the conventional TRAD at 5 days following infection in WI38 cells (Fig. 4A). An approximately 3- to 300-fold reduction in the genome copy numbers of TRAD-143T, -145T, and -199aT was also observed in NHLF and PrSC. The replication of TRADs was also suppressed in SAEC by the insertion of the miRNA complementary sequences, although the expression levels of miR-143, -145, and -199a in SAEC were much lower than those in the other normal cells (Fig. 2). The suppressive effects of insertion of the miRNA target sequences were different among the cells; however, overall, the insertion of miR-199a complementary sequences mediated similar or higher suppressive effects on the replication of TRADs in all the normal cells examined, compared with insertion of the sequences complementary to miR-143 and -145. Replication of TRAD-199aT was inhibited by more than 10-fold in all the normal cells except for SAEC. We also examined the viabilities of the normal cells after infection with the TRADs. No apparent differences in cell viabilities were found among the TRADs by crystal violet staining (data not shown); however, Alamar blue assay showed that the average values of the normal cell viabilities were higher after infection with TRAD-miRT than after infection with the conventional TRAD (Fig. 4B). These results suggest that the suppression of TRAD replication by insertion of the miRNA complementary sequences results in the improvement of the TRAD safety profile in normal cells.

Next, to evaluate whether the reduction in replication of TRAD-miRT was miRNA-dependent, miRNAs were inhib-




Figure 3. Replication and oncolytic activity of TRADs containing the miRNA complementary sequences in the tumor cells. A, a schematic diagram of a TRAD containing the miRNA-regulated E1 gene expression system. ITR: inverted terminal repeat. B, crystal violet analysis of the cytopathic effects of TRADs in the tumor cells. The cells were infected with the TRADs at an MOI of 2 for 2 hours. Three days after infection, the cells were stained with crystal violet. The results are representative of at least 2 independent experiments. C, time-course study of the tumor cell lysis activity of TRADs by Alamar blue assay. The cells were infected with the TRADs at an MOI of 0.4 for 2 hours. At the indicated time points, the viability of the cells was analyzed by Alamar blue assay. The data were normalized by the data of the mock-infected group. D, the viral genome copy numbers of TRADs in the tumor cells. The cells were infected with the TRADs at an MOI of 2 for 2 hours. Three days after infection, the viral genome copy numbers were quantified by real-time PCR. The data was normalized by the data of the conventional TRAD group. E, the E1A mRNA levels in H1299 cells 24 hour after infection with the TRADs. The cells were infected with the TRADs at an MOI of 2 for 1.5 hours. Twenty-four hours after infection, the E1A mRNA levels were determined by real-time RT-PCR. The data was normalized by the data of the conventional TRAD group. All the data are shown as the means \pm SD ($n = 3-6$). *, $P < 0.05$; **, $P < 0.005$.

ited by a 2'-O-methylated antisense oligonucleotide. NHLF and PrSC cells were transfected with the 2'-O-methylated antisense oligonucleotide against miR-143 or -199a, and then the cells were infected with the TRADs, 24 hour after transfection. In the cells transfected with the 2'-O-methylated antisense oligonucleotide against miR-143 or -199a, the reduction in the replication of TRAD-miRT was significantly restored, but the scramble 2'-O-methylated oligonucleotide did not significantly affect the replication of TRAD-miRT (Fig. 4C). These results indicate that the reduction in the replication of TRAD-miRT in the normal cells was miRNA-dependent.





Figure 3. (Continued)

Figure 4. Reduced replication of TRADs in normal human cells by insertion of the miRNA complementary sequences. A, the viral genome copy numbers of TRADs in normal cells. The cells were infected with the TRADs at an MOI of 10 for 2 hours. Five days after infection, the viral genome copy numbers were determined by real-time PCR. B, time-course study of the normal human cell viabilities after infection with TRADs by Alamar blue assay. The cells were infected with the TRADs at an MOI of 10 for 2 hours. At the indicated time points, the viability of the cells was analyzed by Alamar blue assay. The data were normalized by the data of the mock-infected group. C, restoration of TRAD replication in human normal cells by 2'-O-methylated antisense oligonucleotides. The cells were transfected with 50 nmol/L of 2'-O-methylated antisense oligonucleotides for miR-143 or -199a. Twenty-four hours after transfection, the cells were infected with the TRADs at an MOI of 10, and the viral genome copy numbers were determined 5 days after infection with the TRADs. D, the E1A mRNA levels in normal human cells. The cells were infected with the TRADs at an MOI of 10 for 1.5 hours. Twenty-four hours after infection, the E1A mRNA levels were determined by real-time RT-PCR. The data was normalized by the data of the conventional TRAD group. All the data are shown as the means \pm SD ($n = 3-4$). *, $P < 0.05$; **, $P < 0.005$.






Figure 4. (Continued)

E1A expression by TRAD-miRT in normal cells

To determine whether incorporation of the miRNA complementary sequences into the *E1* gene expression cassette decreases the *E1* mRNA levels in normal human cells, real-time RT-PCR analysis for the *E1A* mRNA levels was carried out. The *E1A* mRNA levels were reduced by more than 30% for TRAD-143T, -145T, and -199aT, compared with the parent TRAD, in NHLF (Fig. 4D). The reduction in the *E1A* mRNA levels corresponded to the suppression in replication of TRAD-miRT, indicating that miRNA-mediated reduction in the *E1* gene expression resulted in a reduced replication of TRAD-miRT.

Development of TRADs containing the complementary sequences for liver-specific miRNA

To prevent the replication of TRADs in liver hepatocytes as well as other normal cells, we incorporated not only miR-199a complementary sequences but also sequences complementary to liver-specific miR-122a into the *E1* gene expression cassette, resulting in TRAD-122a/199aT (Fig. 5A). It is well known that Ads have high hepatic tropism, leading to efficient liver accumulation even after local administration. MiR-122a was expressed approximately 100- and 20-fold more abundantly in NHep and Huh-7 cells, respectively, than in the other normal human cells and tumor cells (Fig. 5B); conversely, the other normal cells expressed more than 10-fold lower levels of miR-122a than miR-143, -145, and -199a (data not shown). Incorporation of miR-122a complementary sequences alone significantly reduced the virus genome copy number of TRAD-122aT in NHLF and NHep; however, no statistically significant decrease in the genome copy number of TRAD-122aT was found in PrSC (Fig. 5C). On the other hand, insertion of miR-199a target sequences alone was less efficient than insertion of miR-122a target sequences in NHep, probably due to the lower expression of miR-199a

than miR-122a in NHep. By contrast, insertion of both miR-122a and miR-199a target sequences into the *E1* gene expression cassette efficiently reduced the replication of TRAD-122a/199aT by 10- to 50-fold in all normal cells examined. Significantly reduced replication of TRAD-122a and TRAD-122a/199aT was also found in Huh-7 cells, which are a hepatoma cell line highly expressing miR-122a and are often used as a model of hepatocytes (Supplementary Fig. S2). The incorporation of the miR-145 complementary sequences was also effective for suppressing the TRAD replication in NHep (Supplementary Fig. S3). The *E1A* mRNA levels were reduced for TRAD-122aT and -122a/199aT in NHep (Fig. 5D). In addition, TRAD-122a/199aT efficiently replicated in the tumor cells, resulting in efficient tumor cell lysis (Fig. 5E and F). These results indicate that replication of the TRADs in various types of normal human cells, including liver hepatocytes, is significantly reduced by insertion of the multiple target sequences to both miR-122a and -199a, without influencing the tumor cell lysis activity.

Discussion

The aim of this study was to prevent the replication of TRADs in normal human cells by incorporation of sequences complementary to miRNAs that are selectively downregulated in tumor cells, without altering the tumor cell lysis activity. Currently, there is no appropriate animal model which fully supports the *in vivo* replication of Ads and evaluation of the *in vivo* toxicity caused by oncolytic Ads, and thus it is important to be cautious in regard to oncolytic Ad-induced toxicity. To prevent the *E1* gene expression and replication of oncolytic Ads in normal cells as much as possible, a miRNA-mediated posttranscriptional detargeting system was included in TRADs, in